Gene and microRNA transcriptome analysis of Parkinson's related LRRK2 mouse models

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Dorval, Véronique ^a,b   Mandemakers, Wim ^c,d   Jolivette, Francis ^a,b   Coudert, Laetitia ^a,b   Mazroui, Rachid ^a,b   De Strooper, Bart ^c,d   Hébert, Sébastien S ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MICRORNA; MICRORNA 16; MICRORNA 25; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADRA2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; MOUSE; NONHUMAN; OPALIN GENE; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SYT2 GENE; TRANSCRIPTION REGULATION;

ANIMALS; ARGONAUTE PROTEINS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICRORNAS; MUTATION; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84897517156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085510     Document Type: Article

References (47)

1. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373: 2055-2066.
2. Dickson DW (2012) Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2.
3. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, et al. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57: 918-921. (Pubitemid 40798631)
4. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600. (Pubitemid 39531224)
5. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11: 791-797.
6. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593. (Pubitemid 44781171)
7. Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, et al. (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75: 1008-1021.
8. Ferree A, Guillily M, Li H, Smith K, Takashima A, et al. (2012) Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener Dis 10: 238-241.
9. Dorval V, Hebert SS (2012) LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson's Disease. Front Neurol 3: 12.
10. Habig K, Walter M, Poths S, Riess O, Bonin M (2008) RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9: 83-94.
11. Schulz C, Paus M, Frey K, Schmid R, Kohl Z, et al. (2011) Leucine-rich repeat kinase 2 modulates retinoic acid-induced neuronal differentiation of murine embryonic stem cells. PLoS ONE 6: e20820.
12. Nikonova EV, Xiong Y, Tanis KQ, Dawson VL, Vogel RL, et al. (2012) Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Hum Mol Genet 21: 163-174.
13. Devine MJ, Kaganovich A, Ryten M, Mamais A, Trabzuni D, et al. (2011) Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS ONE 6: e22489.
14. Meister G (2013) Argonaute proteins: functional insights and emerging roles. Nat Rev Genet.
15. Dachsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, et al. (2007) Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord 13: 382-385. (Pubitemid 47449755)
16. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466: 637-641.
17. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64-71.
18. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
19. Djuranovic S, Nahvi A, Green R (2012) miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 336: 237-240.
20. Hu W, Coller J (2012) What comes first: translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res 22: 1322-1324.
21. Westerlund M, Belin AC, Anvret A, Bickford P, Olson L, et al. (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 152: 429-436.
22. Li Y, Liu W, Oo TF, Wang L, Tang Y, et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
23. Li T, Yang D, Sushchky S, Liu Z, Smith WW (2011) Models for LRRK2-Linked Parkinsonism. Parkinsons Dis 2011: 942412.
24. Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, et al. (2013) A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Dis Model Mech 6: 1316-1324.
25. Mandemakers W, Snellinx A, O'Neill MJ, de Strooper B (2012) LRRK2 expression is enriched in the striosomal compartment of mouse striatum. Neurobiol Dis 48: 582-593.
26. Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, et al. (2013) Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem J 453: 101-113.
27. Granic A, Potter H (2013) Mitotic spindle defects and chromosome missegregation induced by LDL/cholesterol-implications for Niemann-Pick C1, Alzheimer's disease, and atherosclerosis. PLoS ONE 8: e60718.
28. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, et al. (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21: 1931-1944.
29. Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, et al. (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol.
30. Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, et al. (2013) LRRK2 regulates tau phosphorylation through direct activation of GSK-3beta. FEBS J.
31. Dorval V, Smith PY, Delay C, Calvo E, Planel E, et al. (2012) Gene network and pathway analysis of mice with conditional ablation of dicer in post-mitotic neurons. PLoS ONE 7: e44060.
32. Hebert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, et al. (2010) Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet 19: 3959-3969.
33. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102: 13944-13949. (Pubitemid 41377683)
34. Bandmann O, Cookson MR (2012) Parkinson disease, cancer, and LRRK2: causation or association? Neurology 78: 772-773.
35. Nelson PT, Hatzigeorgiou AG, Mourelatos Z (2004) miRNP:mRNA association in polyribosomes in a human neuronal cell line. RNA 10: 387-394. (Pubitemid 38240999)
36. Molotski N, Soen Y (2012) Differential association of microRNAs with polysomes reflects distinct strengths of interactions with their mRNA targets. RNA 18: 1612-1623.
37. Khandjian EW, Huot ME, Tremblay S, Davidovic L, Mazroui R, et al. (2004) Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc Natl Acad Sci U S A 101: 13357-13362. (Pubitemid 39209670)
38. Wang WX, Wilfred BR, Hu Y, Stromberg AJ, Nelson PT (2010) Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA 16: 394-404.
39. Nadler JJ, Zou F, Huang H, Moy SS, Lauder J, et al. (2006) Large-scale gene expression differences across brain regions and inbred strains correlate with a behavioral phenotype. Genetics 174: 1229-1236. (Pubitemid 44808295)
40. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010) miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329: 1537-1541.
41. Finnerty JR, Wang W-X, Hébert SS, Wilfred BR, Mao G, et al. (2010) The miR-15/107 Group of MicroRNA Genes: Evolutionary Biology, Cellular Functions, and Roles in Human Diseases. Journal of molecular biology 402: 491-509.
42. Nishi H, Ono K, Iwanaga Y, Horie T, Nagao K, et al. (2010) MicroRNA-15b modulates cellular ATP levels and degenerates mitochondria via Arl2 in neonatal rat cardiac myocytes. J Biol Chem 285: 4920-4930.
43. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C, Lincoln SJ, Lepretre F, et al. (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89: 398-406.
44. Trancikova A, Mamais A, Webber PJ, Stafa K, Tsika E, et al. (2012) Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS ONE 7: e47784.
45. Gareau C, Houssin E, Martel D, Coudert L, Mellaoui S, et al. (2013) Characterization of fragile X mental retardation protein recruitment and dynamics in Drosophila stress granules. PLoS ONE 8: e55342.
46. Smith PY, Delay C, Girard J, Papon MA, Planel E, et al. (2011) MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 20: 4016-4024.
47. Nelson PT, De Planell-Saguer M, Lamprinaki S, Kiriakidou M, Zhang P, et al. (2007) A novel monoclonal antibody against human Argonaute proteins reveals unexpected characteristics of miRNAs in human blood cells. RNA 13: 1787-1792. (Pubitemid 47481686)